Protara Therapeutics, Inc.
TARA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.01 | -0.01 | 0.15 |
| FCF Yield | -32.99% | -176.52% | -88.07% | -46.29% |
| EV / EBITDA | 1.01 | 0.30 | -0.19 | -1.03 |
| Quality | ||||
| ROIC | -28.46% | -59.11% | -60.76% | -27.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.93 | 0.40 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 4.60% | -41.48% | 24.28% | -44.49% |
| Safety | ||||
| Net Debt / EBITDA | 3.22 | 0.79 | 0.27 | 0.62 |
| Interest Coverage | 0.00 | 0.00 | -58.98 | -27.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.21 | 0.00 |
| Cash Conversion Cycle | -4,869.23 | -2,605.31 | -625.08 | -298.38 |